Zacks Investment Research
09 Jul 2026, 16:40 UTC · 2h ago
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
09 Jul 2026, 16:40 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Roche expects its partnered drug with Prothena, prasinezumab, to have peak sales potential exceeding $3.5 billion. — High potential peak sales for a late-stage Parkinson's drug provides a significant valuation catalyst for Prothena.
+0.60Prothena received a $50 million clinical milestone payment in March related to phase III enrollment progress. — Direct cash infusion and validation of clinical progress improve the company's immediate financial position.
+0.40Novo Nordisk is evaluating coramitug in the phase III CLEOPATTRA program for ATTR-CM, with completion expected by 2029. — Advancement into phase III for a first-in-class antibody represents material pipeline progress, though the timeline is long-term.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares have gained 11% due to late-stage program advancement, milestone payments, and a solid cash position.
Evaluating prasinezumab with peak sales potential exceeding $3.5 billion and encouraging long-term clinical evidence.
Making meaningful late-stage progress with the phase III CLEOPATTRA program for ATTR amyloidosis.
[mutual] Novo Nordisk and Prothena have a collaboration portfolio including the evaluation of coramitug.
[mutual] Roche is a partner of Prothena evaluating prasinezumab in a late-stage study.
[a_to_b] Novo Nordisk acquired coramitug, which was initially developed by Prothena, in July 2021.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Barrons
7h ago
